DHCPL | Topical corticosteroids – DHCPL – Risk of withdrawal reactions | Communication To Health Care Professionals | 2022 Oct
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Anagrelide hydrochloride: Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation | Communication To Health Care Professionals | 2022 Aug
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Cefepime hydrochloride – Risk of serious adverse reactions | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Valproate containing medicines – High risk of congenital abnormalities and development disorders | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Clozapine – Induced gastrointestinal hypomotility | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Hydrochlorothiazide – Risk of non-menoloma skin cancer | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Lamotrigine – Risk of Hemophagocytic Lymphohistiocytosis | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Hyoscine Butylbromide – Risk of adverse effects in patients with underlying cardiac disease | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Amphotericin B – Risk of Medication Error | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | EPOETIN ALFA – New warnings on severe cutaneous adverse reaction | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Gadolinium-Based Contrast Agents – Deposition in the brain | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Dolutegravir – Risk of neural tube defects | Communication To Health Care Professionals | 2019 Apr
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers | Communication To Health Care Professionals | 2019 Jun
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers | Communication To Health Care Professionals | 2019 Jun
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers | Communication To Health Care Professionals | 2019 Jul
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers | Communication To Health Care Professionals | 2019 Aug
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Risk of Acute Kidney Injury with concomitant use of Fluoroquinolones and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers – 1 August 2019 | Communication To Health Care Professionals | 2019 Aug
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Pradaxa | Communication To Health Care Professionals | 2019 Aug
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Xarelto | Communication To Health Care Professionals | 2019 Aug
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Eliquis | Communication To Health Care Professionals | 2019 Sep
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | DHCPL for ACE-inhibitor/Angiotensin receptor blocker containing medicines | Communication To Health Care Professionals | 2019 Oct
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Fluoroquinolones: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones | Communication To Health Care Professionals | 2020 Jun
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Sandoz and Novartis: Warning about small increased risk of oral clefts following use in the first 12 weeks of pregnancy | Communication To Health Care Professionals | 2020 Jun
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Ondansetron: Warning about small increased risk of oral clefts following use in the first 12 weeks of pregnancy | Communication To Health Care Professionals | 2020 Jun
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Tyrosine kinase inhibitors | Communication To Health Care Professionals | 2020 Jun
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Fluoropyrimidine containing medicines and related substances: Increased drug exposure and toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency | Communication To Health Care Professionals | 2020 Oct
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Risk of dopamine dysregulation syndrome (DDS) associated with the use of dopaminergic medicines used for the treatment of Parkinson’s disease (PD). | Communication To Health Care Professionals | 2021 Nov
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis | Communication To Health Care Professionals | 2020 Nov
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Dopaminergic medicines used in the treatment of parkinson’s disease: Risk of Dopamine dysregulation syndrome | Communication To Health Care Professionals | 2020 Oct
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Diphenhydramine-containing Medicines | Communication To Health Care Professionals | 2020 Nov
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Eltroxin New Formulation (25 Mcg, 50 Mcg, 75 Mcg, 100 And 200 Mcg Tablets: Increased Adverse Events Reports And Requirement For Patient Therapeutic Monitoring By Healthcare Professionals. | Communication To Health Care Professionals | 2020 Dec
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Increased Risk Of Subclinical Acute Interstitial Nephritis Associated With The Use Of Proton Pump Inhibitors (Ppis) Leading To Acute Kidney Injury And/or Chronic Renal Failure | Communication To Health Care Professionals | 2021 Feb
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Risk Of Drug Induced Liver Injury Associated With The Use Of Metamizole-containing Medicines | Communication To Health Care Professionals | 2021 Mar
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | SAHPRA launches the Med Safety App for self-reporting of suspected Adverse Drug Reactions by the Public and Healthcare Professionals | Communication To Health Care Professionals | 2021 Apr
| 1 | pharmacovigilance | www | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | COVID-19 Vaccine Janssen: Risk of Thrombosis in combination with Thrombocytopenia | Communication To Health Care Professionals | 2021 Nov
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Dopaminergic Medicines used in the treatment of Parkinson’s Disease: Risk of Dopamine Dysregulation Syndrome | Communication To Health Care Professionals | 2021 May
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Selective Serotonin Reuptake Inhibitors (SSRIS) and Serotonin–Norepinephrine Reuptake Inhibitors (SNRIS) associated with the risk of Postpartum Haemorrhage | Communication To Health Care Professionals | 2021 Jun
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | COVID-19 Vaccine Janssen | Communication To Health Care Professionals | 2021 Jul
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | SAHPRA Statement on Adverse Events Following Immunisation (AEFIs) with COVID 19 Vaccines | Communication To Health Care Professionals | 2021 Aug
| 1 | pharmacovigilance | www | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | COMIRNATY® (COVID-19 mRNA Vaccine) -Warning regarding rare cases of Myocarditis and Pericarditis | Communication To Health Care Professionals | 2021 Aug
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | VSIQQ® (Brolucizumab) – A Requirement to Discontinue Treatment with Vsiqq® in Patients who Develop Retinal Vasculitis and/or Retinal Vascular Occlusion, Typically in the Presence of Intraocular Inflammation | Communication To Health Care Professionals | 2021 Nov
| 1 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |
DHCPL | Topical Corticosteroid – Risk of Withdrawal Reactions – Aspen | Communication To Health Care Professionals | 2022 Aug
| 2 | pharmacovigilance | pdf | Download | communication-to-health-care-professionals | pharmacovigilance |